Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Free Cash Flow (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Free Cash Flow for 4 consecutive years, with -$13.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 56.0% to -$13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$103.8 million, a 29.24% decrease, with the full-year FY2025 number at -$103.8 million, down 29.24% from a year prior.
  • Free Cash Flow was -$13.8 million for Q4 2025 at Day One Biopharmaceuticals, down from -$5.8 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $105.0 million in Q3 2024 to a low of -$104.1 million in Q2 2024.
  • A 4-year average of -$27.6 million and a median of -$30.6 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 382.99% in 2024; the steepest drop was 144.54% in 2024.
  • Day One Biopharmaceuticals' Free Cash Flow stood at -$35.3 million in 2022, then fell by 17.1% to -$41.4 million in 2023, then grew by 24.05% to -$31.4 million in 2024, then surged by 56.0% to -$13.8 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Free Cash Flow are -$13.8 million (Q4 2025), -$5.8 million (Q3 2025), and -$24.8 million (Q2 2025).